Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cellipont Bioservices Names Stella Vnook as Chief Scientific Officer | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Cellipont Bioservices Names Stella Vnook as Chief Scientific Officer

Vnook is a biopharmaceutical executive with 20+ years of leadership experience.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Cellipont Bioservices, a contract development and manufacturing organization (CDMO) specializing in cell therapies and gene-modified cell therapies, has appointed Stella Vnook as chief scientific officer.
 
Vnook is a biopharmaceutical executive with 20+ years of leadership experience driving transformational change for global clinical development portfolios from early-stage R&D to commercialization. She has extensive background in cell therapy, as a company founder and patent owner of multiple cell-therapy inventions, such as xenotransplantation of islet cells. 
 
Vnook has built companies around CAR-T, CAR-NK and gene-editing technologies. With extensive experience in manufacturing and commercialization of products, Vnook brings a keen understanding of how to properly position and value products to patients, providers, and payers to successfully launch new drugs and position for patient access and reimbursement coverage.
 
Vnook has a diverse background as an innovative leader overseeing the full product lifecycle for companies of all sizes. Her prior experience includes pharmaceutical research and development as well as work as a Registered Pharmacist specializing in Oncology before she transitioned to executive leadership roles. She was co-founder and CSO of MaiCell Therapeutics and co-founder and CEO of NAKI Therapeutics.  Vnook also held prior leadership roles at Catalent and Merck & Co.
 
“Stella brings to Cellipont decades of scientific experience in cell therapies. Her expertise will be a great asset for the clients we support, as well as for our internal teams.  In addition, with Stella’s past success in both large organizations and as a biotech entrepreneur, she has lived through the challenges our clients face every day. We look forward to her sharing that experience as we move forward,” said Cellipont President & CEO Deborah Wild.
 
Vnook holds a B.A. in microbiology and an R.Ph. in pharmacy from Temple University and an M.B.A. from LaSalle University. She is a candidate for a Ph.D. in Healthcare Administration/ Economics.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters